| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 2 May 2024 | 22 Apr 2024 |
| AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2024; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2024. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(b) of the Listing Regulations and in continuation to our intimation dated April 22, 2024 about meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 2, 2024, we hereby inform that at the said meeting, the Board will also consider a proposal for buy-back of Equity Shares of the Company and other matters incidental and necessary thereto, in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws (As Per BSE Announcement Dated on 26-04-2024) We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details. Pursuant to Regulation 30 of SEBI (LODR), we hereby inform that at the Board Meeting held today, the Board approved appointment of following persons as Additional Non-Executive Independent Director subject to approval of members: 1. Mr. David Rasquinha 2. Mrs. Medha Joshi 3. Mr. Rajesh Dalal 4. Mrs. Simi Thapar Pls find enclosed details towards: 1. Appointment of Cost Auditors 2. Vacancy of Cost Auditors 3. Re-appointment of Secretarial Auditors 4. Re-appointment of Tax Auditors We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details. Outcome of Board Meeting (As Per BSE Announcement Dated on 02.05.2024) In our intimation dated 2nd May 2024, under Regulation 30 of SEBI (LODR) Regulations, 2015, we had inadvertently intimated about change of Cost Auditor. PFA correct intimation for change in cost auditors. (As Per BSE Announcement Dated on 03/05/2024) PFA Board Resolution for Buy Back (As Per BSE Announcement Dated on 06.05.2024) | ||
| Board Meeting | 31 Jan 2024 | 19 Jan 2024 |
| AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve Unaudited Consolidated and Standalone Financial Results for the third quarter ended 31.12.2023. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 ,inter alia, to consider and approve This is with reference to our letter dated 19th January 2024, informing about the Board meeting scheduled on Wednesday, 31st January 2024 to inter-alia consider and take on record the unaudited financial results for the third quarter ended 31st December 2023. Pursuant to Regulation 29(1)(e) of the Listing Regulations, we hereby inform that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 2nd interim dividend for the financial year ending 31st March 2024; b. fixation of Thursday, 8th Dec 2024 as the Record Date for the payment of 2nd interim dividend, if declared. (As Per BSE Announcement Dated on 24.01.2024) The Board in its meeting held today has approved 2nd Interim Dividend. For more details please find enclosed herewith outcome of the Board Meeting. At the Board meeting held today, the Board has inter-alia approved and took on record Unaudited Financial results for the quarter and nine months ended 31st December 2023, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 31.01.2024) | ||
| Board Meeting | 31 Oct 2023 | 19 Oct 2023 |
| AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 inter alia to consider and approve Unaudited Consolidated and Standalone Financial Results for the second quarter and half year ended 30.09.2023 Results for the Second Quarter and Half Year Ended 30th September 2023. PFA herewith results for H1 FY 2024 (As per BSE Announcement Dated on 31/10/2023) Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter ended 30th September 2023 published in the following newspapers on 1st November 2023: 1. Mumbai edition of Business Standard and 2. Mumbai edition of Navakal (As Per BSE Announcement Dated on 01/11/2023) | ||
| Board Meeting | 27 Jul 2023 | 14 Jul 2023 |
| AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 inter alia to consider and approve unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2023. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 ,inter alia, to consider and approve This is with reference to our letter dated 14th July 2023, informing you about the Board meeting scheduled on Thursday, 27th July 2023 to inter-alia consider and take on record the unaudited financial results for the first quarter ended 30th June 2023. Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for: a. declaration of interim dividend, if any, for the financial year ending 31st March 2024; and b. fixation of Friday, 4th August 2023 as the Record Date for the payment of interim dividend, if declared. Board to consider interim dividend at the meeting held on Thursday, 27th July 2023. (As Per BSE Announcement Dated on 24.07.2023) Board approved:- 1. First Interim dividend of Rs. 315 cr. for the year FY 2024. It translates into Rs. 25 per share (1250%) on face value ofRs. 2/- per share. This total dividend ofRs. 25 per share includes a regular dividend ofRs. l0 per share, and an additional Rs. 15 per share, distributed as a special dividend on the commemoration of 50 years of momentous joumey of the Company. 2. Fixed Friday, 4e August 2023 as the Record dale for payment of interim dividend and special dividend. Dividend will be paid on or after I ls August 2023. (As Per BSE Bulletin Dated on 27.07.2023) Outcome of Board Meeting (As per BSE Announcement Dated on 27/07/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
